Aurinia Pharmaceuticals announced that it will present positive data from its Phase 2b clinical trial evaluating the efficacy and safety of voclosporin for the treatment of lupus nephritis, showing that the study had met and confirmed its primary endpoint of complete remission in a statistically significant number of treated patients. The data…
The Lupus Foundation of America (LFA) recently honored Richard A. Rosenbaum, the executive chairman of the law firm Greenberg Traurig, with the Hope Award, based on the firm’s “generosity and long-standing support of lupus research and education,” according to a press release. The award was presented at the foundation’s Evening of Hope Gala in…
The Lupus Research Alliance recently launched a new initiative called the Lupus Clinical Investigators Network (LuCIN) to accelerate the identification and development of new therapies to treat lupus. LuCIN was originally created as a continuation of a project that the Lupus Research Alliance had initiated for drug repurposing…
Researchers have found that a group of proteins in wheat may be responsible for triggering inflammation in chronic conditions such as lupus, rheumatoid arthritis, and multiple sclerosis. The protein could also contribute to the development of non-celiac gluten sensitivity. How gluten, another wheat protein, can harm people who are celiac and non-celiac gluten sensitive is…
Researchers identified 23 genes associated with a predisposition for vitiligo, an autoimmune disease characterized by patches of skin and hair that lack pigmentation. Their discovery may lead to a better understanding of other autoimmune conditions, such as lupus. The study, “Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci…
Singer Lori Jenaire is on a mission beyond sales and charting. With the release of her single — which listed in the Top Five Billboard Hot Singles Sales — “As You Are,” a remake of the 1978 Pharaoah Sander’s R&B classic, Jenaire is pledging a portion of all proceeds from its…
Kevin J. Tracey, MD, CEO and president of The Feinstein Institute for Medical Research, is the winner of the Frederik B. Bang Award for his work on controlling inflammation in the treatment of diseases such as a lupus. Bestowed by The International Endotoxin and Innate Immunity Society (IEIIS) as its highest…
Aurinia Pharmaceuticals announced that seven of the 10 patients with lupus nephritis (LN) enrolled in its AURION study, evaluating short-term predictors of clinical response to voclosporin treatment, achieved complete disease remission at 24 weeks. In addition, the company reported that patients who achieved remission at eight weeks continued in remission at 24 weeks.
Researchers at Temple University Hospital are taking part in a large, global Phase 3 clinical trial to evaluate whether a novel, investigational drug for systemic lupus erythematosus (SLE) is more effective than previously approved medications. This trial (NCT02446912), one of several pivotal and ongoing studies of anifrolumab to treat moderately to severely active SLE,…
Aurinia Pharmaceuticals announced that its AURA-LV clinical trial, assessing voclosporin for the treatment of lupus nephritis (LN), has achieved its primary endpoint at its lower dose — complete disease remission at 24 weeks. Prespecified secondary endpoints at both dose levels were also reached in comparison to placebo, including partial remission as measured…